复星医药：控股子公司药友制药与辉瑞签订许可协议

Core Viewpoint - Fosun Pharma's subsidiary, Yaoyou Pharmaceutical, has entered into a licensing agreement with Pfizer for the development and commercialization of GLP-1R agonists, including YP05002, with significant financial implications for both companies [1] Group 1: Licensing Agreement Details - The licensing agreement grants Pfizer exclusive rights to develop, use, produce, and commercialize GLP-1R agonists globally across all human and animal indications [1] - Yaoyou Pharmaceutical will receive an upfront payment of $15 million and up to $35 million in development milestone payments [1] - Pfizer will also pay up to $158.5 million in sales milestone payments based on the annual net sales performance of the licensed products [1]